Antibody Titer Threshold Predicts Anti‐Candidal Vaccine Efficacy Even though the Mechanism of Protection Is Induction of Cell‐Mediated Immunity
Open Access
- 1 April 2008
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 197 (7) , 967-971
- https://doi.org/10.1086/529204
Abstract
We previously reported that vaccination with Freund’s adjuvant plus the recombinant N-terminus of the candidal adhesin, Als3p (rAls3p-N), protects miKeywords
This publication has 13 references indexed in Scilit:
- Threonine-Rich Repeats Increase Fibronectin Binding in the Candidaalbicans Adhesin Als5pEukaryotic Cell, 2006
- Efficacy of the Anti‐CandidarAls3p‐N or rAls1p‐N Vaccines against Disseminated and Mucosal CandidiasisThe Journal of Infectious Diseases, 2006
- The Anti- Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated CandidiasisInfection and Immunity, 2006
- The Anti- Candida albicans Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised MiceInfection and Immunity, 2005
- Vaccination with Recombinant N-Terminal Domain of Als1p Improves Survival during Murine Disseminated Candidiasis by Enhancing Cell-Mediated, Not Humoral, ImmunityInfection and Immunity, 2005
- Aluminium compounds for use in vaccinesImmunology & Cell Biology, 2004
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Parenchymal Organ, and Not Splenic, Immunity Correlates with Host Survival during Disseminated CandidiasisInfection and Immunity, 2003
- Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working GroupJAMA, 1994
- Adjuvants — a balance between toxicity and adjuvanticityVaccine, 1993